Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati makes and sells prescription medicines, focusing on rare diseases and specialty care, and sells them around the world.
Recordati is an Italian drugmaker that sells prescription medicines, and it has two big personalities. One side treats everyday problems in primary care — things like high blood pressure, high cholesterol, and prostate trouble — through its specialty and primary care business. The other side is the more dramatic one: rare diseases, where Recordati sells treatments for unusual, often inherited conditions that most doctors will rarely if ever see.
The rare disease business is the growth engine. It includes drugs for metabolic disorders, endocrine conditions, and a portfolio that got much bigger when Recordati bought EUSA Pharma, a rare-cancer and rare-disease specialist, and later added more assets. Rare disease drugs tend to be expensive, sold to a small number of specialist doctors and hospitals, and protected by limited competition — which makes them attractive but also means Recordati depends on finding and integrating the right acquisitions. Recordati sells mostly in Europe but also in the United States and other international markets, and it earns money by selling branded prescription drugs, not over-the-counter remedies. Its primary care products are older, steady, cash-generating medicines; they fund the company while the specialty and rare disease side grows. The company has a long habit of paying dividends and has used acquisitions to expand, which is the central tension in the story: it is a reliable cash machine that must keep buying new drugs to stay interesting.
The founder story is genuinely unusual. Recordati was founded in 1926 by Giovanni Recordati, a pharmacist in Correggio, and the family kept control for generations — a rare thing in pharma. That stability helped it stay independent, and the family's stake still shapes how the company is run. Investors mainly watch whether Recordati can keep finding rare disease deals at sensible prices, since that is where the future growth has to come from.
Saved answer · last researched 12 Nov 2026